← All people

Other insiders

Kevin Charles Gorman

Transactions disclosed by this reporting insider. Insider filers can be individuals or organisations.

Source last checked 2026-10-12 01:37 UTC. Reporting dates appear with the records.

Stock growth & value

Stocks linked to collected disclosures. Prices refresh in the background; the chart shows its actual price dates.

Latest stored close
$142.44
NBIX · 2026-10-09 · USD
Stock price change
+$5.09
+3.71% over the displayed dates
Chart dates
2025-10-13 – 2026-10-09
Completed daily price dates

Stock price · move across the chart or use arrow keys

Oct 13, 2025Oct 9, 2026
Starting investment
$10K
2025-10-13 · hypothetical
Investment value
$10.4K
As of 2026-10-09
Estimated gain / loss
+$370.59
+3.71%

Illustration assumes buying this stock at the first displayed close and holding through the last. It does not represent this person's investment or earnings. Uses stored split-adjusted closing prices, without dividends, fees or taxes. Only mapped USD share positions qualify for firm estimates; options, debt and unmapped holdings are excluded. This chart covers the selected stock.

Collected Form 4 activity · 2026-09-11 – 2026-09-11. Priced non-derivative purchases and sales, including scheduled trades; excludes grants, exercises and tax withholding. These totals do not change with the chart period.

Disclosed purchases
—
No priced purchase collected
Disclosed sales
—
No priced sale collected

2 transaction lines

SEC Form 4 records. Grants, exercises, tax withholding and scheduled sales retain their labels.

CompanyActionValue
NBIXNeurocrine Biosciences Inc2026-09-11
Grant
—
NBIXNeurocrine Biosciences Inc2026-09-11
Withheld for tax
$1.2M

Original sources

Related datasets